PHOENIX, May 10, 2017 /PRNewswire/ -- Amnio Technology, LLC, a leading manufacturer of advanced regenerative allografts derived from human amniotic tissues, announced the expansion of its product line with the launch of PalinGen® Inov?Flo™ in the summer of 2017.
PalinGen® lnov?Flo™ is a minimally manipulated liquid allograft derived from human amniotic fluid and is intended for homologous use to supplement tissue for protection, cushioning and lubrication. The product is supplied in volumes of 0.25 cc, 0.50 cc, 1.0 cc, and 2.0 cc.
Christian Beaudry, Chief Scientific Officer stated, "We are very excited about the launch of Inov?Flo™ and have expanded our superior amniotic tissue allograft portfolio."
PalinGen® Inov?Flo™ is manufactured and regulated for human homologous allograft use under 21 CFR Part 1271 and Section 361 of the Public Health Service Act. These tissues are processed and packaged at an FDA registered and American Association of Tissue Banks (AATB) accredited facility.
About Amnio Technology, LLC
Amnio Technology, LLC is a global leader in the development and use of amnion-derived technologies. The company is focused on optimizing the regenerative potential and clinical use of these unique tissues. PalinGen® products do not require fetal sacrifice and recovery is performed with maternal consent during elective Cesarean delivery. Donor tissue is recovered using one of the safest recovery techniques and sterile equipment to minimize bioburden contamination. The amniotic tissues are procured through a network of qualified and trained recovery partners, following stringent screening and recovery protocols in a highly controlled processing environment. Amnio Technology enhances the gift of human birth tissue donation by developing, processing and distributing innovative allografts that provide regenerative therapies to improve quality of life.
PalinGen® is a Registered Trademark of Amnio Technology, LLC.
Amnio Technology, LLC22510 N 18th DrivePhoenix, AZ 85027Phone: 888.232.8550Fax: 888.232.6750www.amniotechnology.com
Advertisement
PalinGen® lnov?Flo™ is a minimally manipulated liquid allograft derived from human amniotic fluid and is intended for homologous use to supplement tissue for protection, cushioning and lubrication. The product is supplied in volumes of 0.25 cc, 0.50 cc, 1.0 cc, and 2.0 cc.
Advertisement
Christian Beaudry, Chief Scientific Officer stated, "We are very excited about the launch of Inov?Flo™ and have expanded our superior amniotic tissue allograft portfolio."
PalinGen® Inov?Flo™ is manufactured and regulated for human homologous allograft use under 21 CFR Part 1271 and Section 361 of the Public Health Service Act. These tissues are processed and packaged at an FDA registered and American Association of Tissue Banks (AATB) accredited facility.
About Amnio Technology, LLC
Amnio Technology, LLC is a global leader in the development and use of amnion-derived technologies. The company is focused on optimizing the regenerative potential and clinical use of these unique tissues. PalinGen® products do not require fetal sacrifice and recovery is performed with maternal consent during elective Cesarean delivery. Donor tissue is recovered using one of the safest recovery techniques and sterile equipment to minimize bioburden contamination. The amniotic tissues are procured through a network of qualified and trained recovery partners, following stringent screening and recovery protocols in a highly controlled processing environment. Amnio Technology enhances the gift of human birth tissue donation by developing, processing and distributing innovative allografts that provide regenerative therapies to improve quality of life.
PalinGen® is a Registered Trademark of Amnio Technology, LLC.
Amnio Technology, LLC22510 N 18th DrivePhoenix, AZ 85027Phone: 888.232.8550Fax: 888.232.6750www.amniotechnology.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/amnio-technology-launches-palingen-inovflo-to-supplement-tissue-for-protection-cushioning-and-lubrication-300454920.html
SOURCE Amnio Technology, LLC
